Lindahl is acting as legal advisor in connection with Nanologica’s rights issue, which was resolved by the board of directors on 29 August 2024 and approved by the extraordinary general meeting on 23 September 2024. The rights issue concerns so called units and will initially, upon full subscription, raise approximately SEK 99.4 million for Nanologica before issue costs. Each unit consists of four shares and one warrant of series TO 2024/2025. Provided the rights issue is fully subscribed and the warrants are fully exercised, the company will raise an additional amount of approximately SEK 33.1 million before issue costs during 2025. The general meeting also authorized the board to decide on an over-allotment issue which, upon full subscription, will raise an additional amount of approximately SEK 20 million before issue costs for the company. The over-allotment issue is conditional upon the rights issue being oversubscribed, and the subscription price will match the subscription price in the rights issue.
The proceeds from the rights issue and any over-allotment issue will primarily be used to strengthen the company's financial position and meet the company’s need for working capital for production and sales within preparative chromatography, with the aim of achieving positive operational cash flow and profitability. The proceeds from the warrants are mainly intended to be used to amortize the company’s remaining loans.
Nanologica’s shares are listed on the Nasdaq Stockholm Main Market, and the company develops, manufactures, and sells advanced materials to pharmaceutical companies. Lindahl’s team consists of Mårten Steen, Olle Swärd Brattström, Erika Svensson, and Helena Lindbäck.
